NeoplasmCaSIDECNCT07695116
Cancer in the Small Developing Island States of the Eastern Caribbean
An observational study of Neoplasm, run by Vaughan A. Lewis Institute for Research and Innovation at 6 sites in 6 countries.
Trial summary
Caribbean studies examining overseas cancer care were lacking patient-level data. Investigators will collect data from patients by establishing a cohort of survivors across six small island developing states (SIDS) (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia and Saint Vincent). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Neoplasm
- What is being tested?
- Overeseas travel for care
- How many people
- 900 participants
- Where
- 6 sitesin 6 countries
- Study dates
- 16 Sep 2024to 15 Aug 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia and Saint Vincent
Who may be able to join
- Primary aim 1 (P1): We will include cancer survivors 18 years of age or older, able to communicate in English or local dialect (without cognitive impairment), with an invasive cancer diagnosis (any cancer site, histology, and year of diagnosis), and having accessed health services in their island of residence (i.e. Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia and Saint Vincent ) due to their cancer. Participation will include written authorization to access each patient's data from medical records in health care institutions and centers
- Primary aim 2 (P2): For the qualitative segment of this proposal, field investigators across the 6 islands will purposefully identify cancer survivors and caregivers of survivors who (1) are receiving or already finished their initial active treatment at the time of the study, (2) received a treatment requiring the intervention of a medical professional (e.g. surgery, chemotherapy, radiotherapy), and (3) are willing to provide written consent for one-on-one interviews and/or focus group discussions.
Who cannot join
- -
Trial locations and contacts
6 sites in 6 countries. Contact the study team or a site near you to ask about taking part.
6 sites in 6 countries
Antigua and Barbuda1 site
Breast Friends Women in Touch
St John's
Dominica1 site
Dominica Cancer Society
Roseau
Grenada1 site
St.George's University
Saint George's
Saint Kitts and Nevis1 site
Essence of hope breast cancer foundation
Basseterre
Saint Lucia1 site
VALIRI
Castries
Saint Vincent and the Grenadines1 site
SCORCH cancer support foundation
Kingstown
About this study
Official title: Overseas Care and Cancer Survivorship in Small Island Developing States of the Eastern Caribbean
Caribbean studies examining overseas cancer care were lacking patient-level data. Investigators will collect data from patients by establishing a cohort of survivors across six small island developing states (SIDS) (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia and Saint Vincent). This proposal is novel for the Caribbean, and it is the first step in identifying the critical performance gaps and leverage points in the process of overseas referral for cancer care. Investigators will compare for the first time, the characteristics and experiences of Caribbean cancer survivors in SIDS who seek care overseas to those who received care on-island.
My overarching goal is to investigate the effects of overseas travel for care on patient-centered outcomes in Caribbean SIDS, and to build a research resource to study cancer survival, as I develop my career as an independent mixed-method investigator.
Read more
Our primary aims are to (P1): Map patterns of overseas travel for cancer care among cancer survivors of six member states of the OECS and (P2): Explore the lived experience of cancer survivors and caregivers and how overseas travel for care affects their social support systems.
Investigators anticipate that (H1) a substantial proportion of cancer survivors travel outside of their resident country for cancer. We expect certain destinations to be more frequented among cancer survivors by individual characteristics (cancer site, stage and country of residence). We also expect that (H2) overseas care may be associated with both challenges and adaptations in social support systems, as explored qualitatively through survivor and caregiver accounts.
Read the detailed description
CaSIDEC is an acronym for "Cancer in SIDS of the Eastern Caribbean". Our overarching ambition is to explore how overseas travel for care may affect key domains of cancer survivorship. Survivorship will be our long-term focus and goes beyond survival as commonly measured in clinical trials (i.e. time to death from diagnosis) and will include measures on how individuals experience life with cancer. In this study, overseas care will be considered as any travel across international country borders (including the Caribbean) regardless of the payment mechanism (e.g. out of pocket or government subsidized).
As a first step, investigators wish to contribute towards building research capacity in SIDS. The CaSIDEC study aims to generate foundational evidence on transnational cancer care pathways and survivorship in SIDS of the Eastern Caribbean. Given the limited availability of standardized epidemiological data in this region, investigators wish to establish data resources, measurement approaches, and analytic frameworks necessary to support future hypothesis-driven and causal research on this topic.
In terms of impact, the data from the current study will guide decisions at the patient, provider and policy level. It will inform notably decisions on how overseas referral pathways should be organized across the OECS subregion.
- Conditions
- Neoplasm
- Being tested
- Overeseas travel for care
- Keywords
- cancer, health services, health disparities, small islands, Caribbean, outcomes, medical tourism, early detection
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Overeseas travel for careOther
Cancer survivors who travel overseas travel for care (observation)
| Study group | Role | What they receive |
|---|---|---|
| Informal caregivers | Informal caregivers of cancer survivors diagnosed in the Eastern Caribbean Receives: Other: Overeseas travel for care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Destination country for cancer treatment
We will map and characterize patterns of overseas care.We will compute the proportion or cancer survivors who travelledtraveled overseas for diagnosis and treatment among the entire sample. The proportion of overseas travel will be computed as well by cancer site, OECS country, period of diagnosis, and type of diagnostics and treatment accessed. Where possible we will characterize overseas travel by region (Caribbean, North America, South America, Europe, and other) and by destination country.
Measured: At inclusion (0 days)
Social support system
Qualitative interviews for social support will be initiated by an introductory question "describe the support you received during the cancer journey", then guided by questions and prompts "who", "what was the relationship to you? such as a family, friend, neighbours" and "when". Participants will be encouraged to focus on aspects of the day-to-day logistics and travel arrangements, experience living overseas.
Measured: At inclusion (0 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2026
- Study start16 Sep 2024
- Primary completion15 Aug 2028 (estimated)
- Study completion15 Aug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for NeoplasmStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 900 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vaughan A. Lewis Institute for Research and Innovation
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr Aviane Auguste, McGill University
- Investigators
- Aviane Auguste, PhD, Principal investigator, Vaughan A. Lewis Institute for Research and Innovation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07695116
- Sponsor's protocol ID
- A10-M79-24A
- Acronym
- CaSIDEC
- Status last verified
- Jul 2026
- First submitted
- 19 Nov 2024
- Last updated
- 10 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymised data set containing basic sociodemographic and clincal characteristics of the persons included in the final sample.
Publications
Johnson SB, Black T, Atabe B; CaSIDEC study group; Auguste A. Mapping stakeholders for developing cancer research in Small Island Developing States: a descriptive study from the Eastern Caribbean. BMJ Open. 2026 Aug 3;16(8):e110521. doi: 10.1136/bmjopen-2025-110521.
PubMed 42547239Auguste A; CaSIDEC Study Group. Overseas Care and Cancer Survivorship in Small Island Developing States of the Eastern Caribbean: Protocol for a Multicountry Mixed Methods Study (CaSIDEC Study). JMIR Res Protoc. 2026 Jul 31;15:e90930. doi: 10.2196/90930.
PubMed 42536966
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Overseas Care and Cancer Survivorship in Small Island Developing States of the Eastern Caribbean
- ClinicalTrials.gov ID
- NCT07695116
- Acronym / sponsor ID
- CaSIDEC / A10-M79-24A
- Conditions
- Neoplasm
- Keywords
- cancer, health services, health disparities, small islands, Caribbean, outcomes, medical tourism, early detection
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 900 participants (estimated)
- Lead sponsor
- Vaughan A. Lewis Institute for Research and InnovationUniversity, hospital or other
- Study start
- 16 Sep 2024 (actual)
- Primary completion
- 15 Aug 2028 (estimated)
- Study completion
- 15 Aug 2028 (estimated)
- First posted
- 10 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Caribbean studies examining overseas cancer care were lacking patient-level data. Investigators will collect data from patients by establishing a cohort of survivors across six small island developing states (SIDS) (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia and Saint Vincent). This proposal is novel for the Caribbean, and it is the first step in identifying the critical performance gaps and leverage points in the process of overseas referral for cancer care. Investigators will compare for the first time, the characteristics and experiences of Caribbean cancer survivors in SIDS who seek care overseas to those who received care on-island.
My overarching goal is to investigate the effects of overseas travel for care on patient-centered outcomes in Caribbean SIDS, and to build a research resource to study cancer survival, as I develop my career as an independent mixed-method investigator.
Our primary aims are to (P1): Map patterns of overseas travel for cancer care among cancer survivors of six member states of the OECS and (P2): Explore the lived experience of cancer survivors and caregivers and how overseas travel for care affects their social support systems.
Investigators anticipate that (H1) a substantial proportion of cancer survivors travel outside of their resident country for cancer. We expect certain destinations to be more frequented among cancer survivors by individual characteristics (cancer site, stage and country of residence). We also expect that (H2) overseas care may be associated with both challenges and adaptations in social support systems, as explored qualitatively through survivor and caregiver accounts.
Detailed description
CaSIDEC is an acronym for "Cancer in SIDS of the Eastern Caribbean". Our overarching ambition is to explore how overseas travel for care may affect key domains of cancer survivorship. Survivorship will be our long-term focus and goes beyond survival as commonly measured in clinical trials (i.e. time to death from diagnosis) and will include measures on how individuals experience life with cancer. In this study, overseas care will be considered as any travel across international country borders (including the Caribbean) regardless of the payment mechanism (e.g. out of pocket or government subsidized).
As a first step, investigators wish to contribute towards building research capacity in SIDS. The CaSIDEC study aims to generate foundational evidence on transnational cancer care pathways and survivorship in SIDS of the Eastern Caribbean. Given the limited availability of standardized epidemiological data in this region, investigators wish to establish data resources, measurement approaches, and analytic frameworks necessary to support future hypothesis-driven and causal research on this topic.
In terms of impact, the data from the current study will guide decisions at the patient, provider and policy level. It will inform notably decisions on how overseas referral pathways should be organized across the OECS subregion.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Informal caregivers | – | Other: Overeseas travel for careInformal caregivers of cancer survivors diagnosed in the Eastern Caribbean |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia and Saint Vincent
Key inclusion criteria (2 listed)
- Primary aim 1 (P1): We will include cancer survivors 18 years of age or older, able to communicate in English or local dialect (without cognitive impairment), with an invasive cancer diagnosis (any cancer site, histology, and year of diagnosis), and having accessed health services in their island of residence (i.e. Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia and Saint Vincent ) due to their cancer. Participation will include written authorization to access each patient's data from medical records in health care institutions and centers
- Primary aim 2 (P2): For the qualitative segment of this proposal, field investigators across the 6 islands will purposefully identify cancer survivors and caregivers of survivors who (1) are receiving or already finished their initial active treatment at the time of the study, (2) received a treatment requiring the intervention of a medical professional (e.g. surgery, chemotherapy, radiotherapy), and (3) are willing to provide written consent for one-on-one interviews and/or focus group discussions.
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Overeseas travel for careCancer survivors who travel overseas travel for care (observation) | Other | Informal caregivers |
Primary outcome
Destination country for cancer treatment
Time frame: At inclusion (0 days)
We will map and characterize patterns of overseas care.We will compute the proportion or cancer survivors who travelledtraveled overseas for diagnosis and treatment among the entire sample. The proportion of overseas travel will be computed as well by cancer site, OECS country, period of diagnosis, and type of diagnostics and treatment accessed. Where possible we will characterize overseas travel by region (Caribbean, North America, South America, Europe, and other) and by destination country.
Social support system
Time frame: At inclusion (0 days)
Qualitative interviews for social support will be initiated by an introductory question "describe the support you received during the cancer journey", then guided by questions and prompts "who", "what was the relationship to you? such as a family, friend, neighbours" and "when". Participants will be encouraged to focus on aspects of the day-to-day logistics and travel arrangements, experience living overseas.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2026.
- Derived from this study: PubMed 42547239Johnson SB, Black T, Atabe B; CaSIDEC study group; Auguste A. Mapping stakeholders for developing cancer research in Small Island Developing States: a descriptive study from the Eastern Caribbean. BMJ Open. 2026 Aug 3;16(8):e110521. doi: 10.1136/bmjopen-2025-110521.
- Derived from this study: PubMed 42536966Auguste A; CaSIDEC Study Group. Overseas Care and Cancer Survivorship in Small Island Developing States of the Eastern Caribbean: Protocol for a Multicountry Mixed Methods Study (CaSIDEC Study). JMIR Res Protoc. 2026 Jul 31;15:e90930. doi: 10.2196/90930.
- Individual participant dataSharing planned: Yes. Anonymised data set containing basic sociodemographic and clincal characteristics of the persons included in the final sample.
Related trials for Neoplasm
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Aviane Auguste, PhD principal investigator
Vaughan A. Lewis Institute for Research and Innovation
6 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neoplasm, run by Vaughan A. Lewis Institute for Research and Innovation at 6 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 10 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in Antigua and Barbuda, Dominica, Grenada, Saint Kitts and Nevis, Saint Lucia and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Destination country for cancer treatment (time frame: At inclusion (0 days)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07695116, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2026.